Chenofalk ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013348-35-NL
(EUCTR)
04/08/200903/07/2009(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. - Bile acid-FXR-FGF19 functioning in Crohn's disease Patients with quiescent Crohn’s colitis, defined as a Crohn’s Disease Activity Index <150 ; non-IBD patients will serve as disease controls.
MedDRA version: 9.1;Level: LLT;Classification code 10011400;Term: Crohn's colitis
MedDRA version: 9.1;Classification code 10011401;Term: Crohn's disease
MedDRA version: 9.1;Classification code 10011402;Term: Crohn's disease (colon)
Trade Name: Chenofalk
Product Name: Chenofalk
Product Code: RVG 07151
INN or Proposed INN: CHENODEOXYCHOLIC ACID
Other descriptive name: Chenodiol
University Medical Center UtrechtNULLNot RecruitingFemale: yes
Male: yes
Netherlands